Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
4 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
TRAIL gene therapy: from preclinical development to clinical application.
Curr Gene Ther. 2009 Feb;9(1):9-19. doi: 10.2174/156652309787354612.
Curr Gene Ther. 2009.
PMID: 19275567
Free PMC article.
Review.
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
VanOosten RL, Earel JK Jr, Griffith TS.
VanOosten RL, et al. Among authors: earel jk jr.
Apoptosis. 2007 Mar;12(3):561-71. doi: 10.1007/s10495-006-0009-9. Epub 2006 Dec 30.
Apoptosis. 2007.
PMID: 17195089
Item in Clipboard
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL, Earel JK Jr, Griffith TS.
VanOosten RL, et al. Among authors: earel jk jr.
Cancer Gene Ther. 2006 Jun;13(6):628-32. doi: 10.1038/sj.cgt.7700939.
Cancer Gene Ther. 2006.
PMID: 16456549
Item in Clipboard
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK Jr, VanOosten RL, Griffith TS.
Earel JK Jr, et al.
Cancer Res. 2006 Jan 1;66(1):499-507. doi: 10.1158/0008-5472.CAN-05-3017.
Cancer Res. 2006.
PMID: 16397266
Item in Clipboard
Cite
Cite